Every 10-Q that Nuvectis Pharma, Inc. (NVCT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NVCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NVCT filings page.
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, reported a net loss of $7.0 million for the quarter and $13.1 million for the six months ended June 30, 2026, with no product revenue. Research and development spending rose to $4.7 million in the quarter and $8.8 million year-to-date, driven mainly by clinical and manufacturing costs, while general and administrative expenses declined modestly.
Cash and cash equivalents were $22.2 million on June 30, 2026. In July 2026 the company completed a public equity offering of 5,750,000 shares at $20.00, generating $115.0 million in gross and approximately $106.3 million in net proceeds; management believes this, together with existing cash, will fund planned operations for at least 12 months. Shares outstanding increased from 26.7 million on June 30 to about 32.6 million on July 31, 2026.
In June 2026 Nuvectis licensed global (ex-China and certain territories) rights to NXP100, an oral Factor B inhibitor for complement-related diseases, and NXP200, a brain-penetrant paradox breaker BRAF inhibitor, from Haisco. The agreement became effective upon the July offering and included a $20.0 million upfront payment and potential milestones of up to approximately $1.4 billion, plus tiered royalties, expanding the pipeline alongside existing oncology candidates NXP900 and NXP800.
Nuvectis Pharma reported first-quarter 2026 results, continuing as a clinical-stage oncology company with no product revenue. Net loss was $6.1 million, compared with $5.3 million a year earlier, driven by higher research and development and public-company costs.
Research and development expenses were $4.1 million and general and administrative expenses were $2.2 million. Cash and cash equivalents totaled $25.1 million at March 31 2026, which management believes can fund operations for at least 12 months.
The accumulated deficit reached $105.7 million. Shares outstanding rose to 26,525,533, reflecting equity-based compensation and modest use of the at-the-market program, which still has $60.0 million capacity within a broader $150.0 million shelf registration. Lead asset NXP900 remains in Phase 1b development.
Nuvectis Pharma (NVCT) reported Q3 2025 results showing higher operating spending as clinical programs progressed and licensing costs increased. Cash and cash equivalents were $35.4 million as of September 30, 2025, compared with $18.5 million at year-end 2024. The company posted a Q3 net loss of $7.5 million and a nine‑month net loss of $19.1 million. A warrant term extension recorded as an $2.4 million effect increased the total net loss attributable to common shareholders in Q3.
Operating drivers: R&D expense rose to $5.8 million in Q3 (from $2.8 million) mainly due to a $2.0 million license fee for NXP900 and higher clinical costs; G&A was $2.0 million (from $1.5 million). Year‑to‑date, R&D reached $13.1 million and G&A $6.9 million. To fund operations, Nuvectis raised capital via equity: in February 2025 it sold 3,105,000 shares at $5.00 for $14.0 million net, and in Q3 it sold 1,707,309 shares under its ATM for $13.5 million gross ($13.1 million net). Management believes current cash funds planned operations for at least 12 months.
Pipeline: NXP900 advanced into Phase 1b in August 2025; a DDI study classified it as a weak CYP3A inhibitor. The company issued a final update for NXP800 in July and will not pursue further development in ovarian cancer while assessing other indications.